Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday.  The ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...